Kezdőlap・Részvénylista・United Therapeutics Corp

United Therapeutics Corp

Lezárt

SzektorEgészségügy

513.25 1.16

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

497.96

Maximum

508.7

Fő mutatók
By Trading Economics
Bevétel	58M 333M
Értékesítés	1.8M 783M
P/E Szektor átlag	18.971 57.002
Egy részvényre jutó nyereség	7.27
Profit margin	42.512
Munkavállalók	1,400
EBITDA	32M 376M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+31.1% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. okt. 28.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-3B 23B
Előző nyitás	512.09
Előző zárás	513.25

Hangulat hírek alapján

By Acuity

56%

44%

265 / 340 Rangsor szerint Healthcare

United Therapeutics Corp Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 13. 19:51 UTC

United Therapeutics Corp shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

2026. aug. 12. 23:01 UTC

United Therapeutics Corp shares are higher in after-market trading, supported by easing concerns over Federal Reserve rate hikes amid rising consumer prices.

2026. aug. 11. 23:02 UTC

United Therapeutics Corp is trading lower in after-market hours, continuing a trend of three consecutive daily declines without any specific news driving the movement.

2026. aug. 10. 20:06 UTC

United Therapeutics Corp shares are lower during Monday's session, with no specific news identified to explain the decline amid broader market volatility.

2026. aug. 7. 19:51 UTC

Social Media

News

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

2026. aug. 6. 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

2026. aug. 5. 20:02 UTC

News

Social Media

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

2026. aug. 4. 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

2026. aug. 3. 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

2026. júl. 30. 14:36 UTC

Event

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

2026. júl. 29. 20:51 UTC

Event

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

2026. júl. 28. 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

2026. júl. 24. 16:36 UTC

News

Social Media

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

2026. júl. 22. 19:41 UTC

News

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.

2026. júl. 21. 16:56 UTC

United Therapeutics Corp is seeing modest gains today, with positive sentiment from Asian markets contributing to overall investor optimism. No specific news was identified.

Társak összehasonlítása

Árváltozás

United Therapeutics Corp Előrejelzés

Célár

By TipRanks

31.1% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 655.13 USD 31.1%

Magas 714 USD

Alacsony 515 USD

9 Wall Street elemző 12 hónapos célárain alapulva a(z)United Therapeutics Corp termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

9 ratings

Vétel

Tartás

Eladás

9 Wall Street elemző célárain alapulva a(z)United Therapeutics Corp termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

265 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.